A 53-year-old man presented to our department with acute urinary retention and an approximate 8-year history of frequent urination, dysuria, poor urinary stream and nocturia. His prostate-specific antigen (PSA) values were normal (<4 ng/ml) upon repeated testing. The patient was diagnosed with benign prostatic hyperplasia, although there was no significant improvement in his symptoms after treatment with oral finasteride and doxazosin. He then underwent transurethral resection of the prostate in February 2013, and histopathological examination showed adenocarcinoma of the prostate. His treatment regimen included daily oral bicalutamide and subcutaneous injection of Zoladex once per month. Three months later, radical prostatectomy was performed, and a prostate histopathological examination indicated primary urothelial carcinoma with glandular differentiation. His PSA values were normal (<4 ng/ml) before and after the radical prostatectomy. After the second operation, the patient received chemotherapy with gemcitabine and cisplatin. Two months later, magnetic resonance imaging (MRI) indicated local tumor recurrence. The patient was treated with chemotherapy combined with radiotherapy for 2 months, and subsequent MRI results showed that the recurrent tumor volume was significantly reduced. As a result, radiotherapy was stopped. The patient remains alive, and his general condition has clearly improved.

Keywords:
Urothelial carcinoma, Prostate, Glandular differentiation
1.
Esrig D, Freeman JA: Transitional cell carcinoma involving the prostate with a proposed staging classification for stromal invasion. J Urol 1996;156:1071-1076.
2.
Reese JH, Freiha FS: Transitional cell carcinoma of the prostate in patients undergoing radical cystoprostatectomy. J Urol 1992;147:92-95.
3.
Melicow MM, Hollowell JW: Intra-urothelial cancer: carcinoma in situ, Bowen's disease of the urinary system: discussion of thirty cases. J Urol 1952;68:763-772.
4.
Elbe N, Sauter G, Epstein JI: Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs. International Agency for Research on Cancer (IARC). Oxford, Oxford University Press, 2004.
5.
Cheville JC, Dundore PA, Bostwick DG, Lieber MM, Batts KP, Sebo TJ, Farrow GM: Transitional cell carcinoma of the prostate: clinicopathologic study of 50 cases. Cancer 1998;82:703-707.
6.
Walsh DL, Chang SS: Dilemmas in the treatment of urothelial cancers of the prostate. Urol Oncol 2009;27:352-357.
7.
Billis A, Schenka AA: Squamous and/or glandular differentiation in urothelial carcinoma: prevalence and significance in transurethral resections of the bladder. Int Urol Nephrol 2001;33:631-633.
© 2014 S. Karger AG, Basel
2014
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.